Nicoderm + Aveva-University of Maryland, Baltimore-nicotine dependence

This designation refers to a bioequivalence research study conducted by the University of Maryland, Baltimore, comparing two FDA-approved nicotine transdermal delivery systems: the brand-name Nicoderm CQ (manufactured by Alza) and the generic Aveva nicotine patch (manufactured by Aveva Drug Delivery Systems). Both products are 21 mg/24-hour nicotine patches indicated for the treatment of nicotine dependence and smoking cessation. The study is a single-dose, open-label, 2-way crossover trial designed to evaluate the effect of standardized heat application on the release and systemic absorption of nicotine from these two distinct patch formulations. Although both patches deliver the same dose of nicotine—a small molecule nicotinic acetylcholine receptor agonist—they differ in their physical dimensions, adhesive components, and inactive excipients.

Brand names

Nicoderm CQAveva nicotine patch

Other names

nicotine transdermal delivery system